🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Tianshuang Wu

AbbVie (United States)

ORCID: 0009-0007-4205-9579
Immunology and MicrobiologyMedicineEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)”.

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

British Journal of Dermatology(2023)10.1093/bjd/ljad252
N/A
0.662DataRank · unranked
22 citations

Jerry Bagel, Stephen K. Tyring, Hwanhee Hong, Lev Pavlovsky, Ronald Vender +11 more